Marker Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders, where three proposals were voted on and all were approved. The company also terminated its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC.